Expression of ribosomal proteins in normal and cancerous human prostate tissue

Abstract

Few quantifiable tissue biomarkers for the diagnosis and prognosis of prostate cancer exist. Using an unbiased, quantitative approach, this study evaluates the potential of three proteins of the 40S ribosomal protein complex as putative biomarkers of malignancy in prostate cancer. Prostate tissue arrays, constructed from 82 patient samples (245 tissue cores, stage pT3a or pT3b), were stained for antibodies against three ribosomal proteins, RPS19, RPS21 and RPS24. Semi-automated Ox-DAB signal quantification using ImageJ software revealed a significant change in expression of RPS19, RPS21 and RPS24 in malignant vs non-malignant tissue (p<0.0001). Receiver operating characteristics curves were calculated to evaluate the potential of each protein as a biomarker of malignancy in prostate cancer. Positive likelihood ratios for RPS19, RPS21 and RPS24 were calculated as 2.99, 4.21, and 2.56 respectively, indicating that the overexpression of the protein is correlated with the presence of disease. Triple-labelled, quantitative, immunofluorescence (with RPS19, RPS21 and RPS24) showed significant changes (p<0.01) in the global intersection coefficient, a measure of how often two fluorophore signals intersect, for RPS19 and RPS24 only. No change was observed in the co-localization of any other permutations of the three proteins. Our results show that RPS19, RPS21 or RPS24 are upregulated in malignant tissue and may serve as putative biomarkers for prostate cancer.

High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue

“…All proteins present in Group 1 show increased abundance in cancer.These are ribosomal proteins that participate in biological processes such as translational elongation and protein localization to organelle (based on gene ontology) and belong to the KEGG ribosome pathway. This is in agreement with previous studies, showing that various ribosomal proteins are up-regulated in prostate cancer[24,25]. Ribosomal protein-based cancer signature has been recently proposed based on the expression of ribosomal proteins in several human tissues and primary cells[26].…”

BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration

“…Major components of the ribosome (ribosomal proteins e.g. RPS-19, -21, -24 and ribosomal RNA) are upregulated in prostate cancer (PCa) [2,3]. BRF1 expression is elevated and associated with poor prognosis in hepatocellular, breast and gastric cancers [4][5][6] but its role in PCa remains unclear.…”

Identification Of Both Shared And Specific Potential Molecular Mechanisms Of Arvc And Dcm Based On A Genome-Wide Microarray Dataset

“…Finally, the mutations of RPL18A and RPL31 have been proven to be associated with Diamond-Blackfan anemia (DBA) [58], and RPL15 was demonstrated as a new gene involved in DBA [59], which may decrease the blood supply to myocardial cells to some degree. Results from Arthurs C et al suggested that expression of RPS21 increased in in malignant tissue and may serve as biomarkers for cancer [60]. Similarly, RSL21 has been reported may be a biomarker of cervical intra-epithelial neoplasia 1 [61], and loss of the heterozygosity and decreased expression of RPL14 might be an earlier event in the tumorigenesis of the esophagus [62].…”